FDA Approves Medtronic Evolut FX+
FDA has approved the Medtronic Evolut FX+ transcatheter aortic valve replacement system to treat symptomatic severe aortic stenosis. The company says the latest Evolut system maintains the valve performance benefits of the legacy platform and is designed to facilitate coronary access. Medtronic says it expects a full product launch in the summer of 2024.